Cargando…

Mesenchymal stromal cell extracellular vesicles for multiple sclerosis in preclinical rodent models: A meta-analysis

INTRODUCTION: Extracellular vesicles (EVs), especially mesenchymal stem (stromal) cell-derived EVs (MSC-EVs), have gained attention as potential novel treatments for multiple sclerosis (MS). However, their effects remain incompletely understood. Thus, the purpose of this meta-analysis was to systema...

Descripción completa

Detalles Bibliográficos
Autores principales: Xun, Chengfeng, Deng, Huiyin, Zhao, Jing, Ge, Lite, Hu, Zhiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673165/
https://www.ncbi.nlm.nih.gov/pubmed/36405749
http://dx.doi.org/10.3389/fimmu.2022.972247
_version_ 1784832892756557824
author Xun, Chengfeng
Deng, Huiyin
Zhao, Jing
Ge, Lite
Hu, Zhiping
author_facet Xun, Chengfeng
Deng, Huiyin
Zhao, Jing
Ge, Lite
Hu, Zhiping
author_sort Xun, Chengfeng
collection PubMed
description INTRODUCTION: Extracellular vesicles (EVs), especially mesenchymal stem (stromal) cell-derived EVs (MSC-EVs), have gained attention as potential novel treatments for multiple sclerosis (MS). However, their effects remain incompletely understood. Thus, the purpose of this meta-analysis was to systematically review the efficacy of MSC-EVs in preclinical rodent models of MS. METHODS: We searched PubMed, EMBASE, and the Web of Science databases up to August 2021 for studies that reported the treatment effects of MSC-EVs in rodent MS models. The clinical score was extracted as an outcome. Articles were peer-reviewed by two authors based on the inclusion and exclusion criteria. This meta-analysis was conducted using Stata 15.1 and R. RESULTS: A total of twelve animal studies met the inclusion criteria. In our study, the MSC-EVs had a positive overall effect on the clinical score with a standardized mean difference (SMD) of -2.17 (95% confidence interval (CI)):-3.99 to -0.34, P = 0.01). A significant amount of heterogeneity was observed among the studies. CONCLUSIONS: This meta-analysis suggests that transplantation of MSC-EVs in MS rodent models improved functional recovery. Additionally, we identified several critical knowledge gaps, such as insufficient standardized dosage units and uncertainty regarding the optimal dose of MSC-EVs transplantation in MS. These gaps must be addressed before clinical trials can begin with MSC-EVs.
format Online
Article
Text
id pubmed-9673165
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96731652022-11-19 Mesenchymal stromal cell extracellular vesicles for multiple sclerosis in preclinical rodent models: A meta-analysis Xun, Chengfeng Deng, Huiyin Zhao, Jing Ge, Lite Hu, Zhiping Front Immunol Immunology INTRODUCTION: Extracellular vesicles (EVs), especially mesenchymal stem (stromal) cell-derived EVs (MSC-EVs), have gained attention as potential novel treatments for multiple sclerosis (MS). However, their effects remain incompletely understood. Thus, the purpose of this meta-analysis was to systematically review the efficacy of MSC-EVs in preclinical rodent models of MS. METHODS: We searched PubMed, EMBASE, and the Web of Science databases up to August 2021 for studies that reported the treatment effects of MSC-EVs in rodent MS models. The clinical score was extracted as an outcome. Articles were peer-reviewed by two authors based on the inclusion and exclusion criteria. This meta-analysis was conducted using Stata 15.1 and R. RESULTS: A total of twelve animal studies met the inclusion criteria. In our study, the MSC-EVs had a positive overall effect on the clinical score with a standardized mean difference (SMD) of -2.17 (95% confidence interval (CI)):-3.99 to -0.34, P = 0.01). A significant amount of heterogeneity was observed among the studies. CONCLUSIONS: This meta-analysis suggests that transplantation of MSC-EVs in MS rodent models improved functional recovery. Additionally, we identified several critical knowledge gaps, such as insufficient standardized dosage units and uncertainty regarding the optimal dose of MSC-EVs transplantation in MS. These gaps must be addressed before clinical trials can begin with MSC-EVs. Frontiers Media S.A. 2022-11-04 /pmc/articles/PMC9673165/ /pubmed/36405749 http://dx.doi.org/10.3389/fimmu.2022.972247 Text en Copyright © 2022 Xun, Deng, Zhao, Ge and Hu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Xun, Chengfeng
Deng, Huiyin
Zhao, Jing
Ge, Lite
Hu, Zhiping
Mesenchymal stromal cell extracellular vesicles for multiple sclerosis in preclinical rodent models: A meta-analysis
title Mesenchymal stromal cell extracellular vesicles for multiple sclerosis in preclinical rodent models: A meta-analysis
title_full Mesenchymal stromal cell extracellular vesicles for multiple sclerosis in preclinical rodent models: A meta-analysis
title_fullStr Mesenchymal stromal cell extracellular vesicles for multiple sclerosis in preclinical rodent models: A meta-analysis
title_full_unstemmed Mesenchymal stromal cell extracellular vesicles for multiple sclerosis in preclinical rodent models: A meta-analysis
title_short Mesenchymal stromal cell extracellular vesicles for multiple sclerosis in preclinical rodent models: A meta-analysis
title_sort mesenchymal stromal cell extracellular vesicles for multiple sclerosis in preclinical rodent models: a meta-analysis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673165/
https://www.ncbi.nlm.nih.gov/pubmed/36405749
http://dx.doi.org/10.3389/fimmu.2022.972247
work_keys_str_mv AT xunchengfeng mesenchymalstromalcellextracellularvesiclesformultiplesclerosisinpreclinicalrodentmodelsametaanalysis
AT denghuiyin mesenchymalstromalcellextracellularvesiclesformultiplesclerosisinpreclinicalrodentmodelsametaanalysis
AT zhaojing mesenchymalstromalcellextracellularvesiclesformultiplesclerosisinpreclinicalrodentmodelsametaanalysis
AT gelite mesenchymalstromalcellextracellularvesiclesformultiplesclerosisinpreclinicalrodentmodelsametaanalysis
AT huzhiping mesenchymalstromalcellextracellularvesiclesformultiplesclerosisinpreclinicalrodentmodelsametaanalysis